text
our pipeline

Targeting ACDs in which serotonin is disrupted


CT38 Cortene’s peptide agonist, which is selective for CRFR2, has completed multiple studies including:
CT38: Test Tubes test-tubes

in vitro studies

CT38: Mouse mouse

in vivo studies
in multiple species

CT38: Man man

a Phase 1 clinical trial
in healthy humans

CT38: Group Group

a proof-of-concept Phase 2
clinical trial in patients

These have enabled us to determine the safe and effective dosing required to downregulate CRFR2. They have also confirmed that CT38 binds only to CRFR2 and is cleared from the body within hour

Pipeline

Our platform allows CT38 to be utilized in several indications.
We are ready to begin Phase 2 clinical trials in Parkinson’s and Alzheimer’s.

Indication
Animal
Phase 1
Phase 2
Phase 3
Parkinson's
Alzheimer's
MEcfs